Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocrelizumab - Biogen/Genentech

Drug Profile

Ocrelizumab - Biogen/Genentech

Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; Ocrevus; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 19 Sep 2019 Roche initiates phase III trial for Multiple sclerosis (Relapsing-remitting) in Australia, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Denmark, Finland, France, Germany, Hungary, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, USA (IV) before September 2019 (NCT03085810)
  • 19 Sep 2019 Phase-III clinical trials in Multiple sclerosis (Relapsing- remitting) in Kuwait, Lebanon (IV) before September 2019 (NCT03085810)
  • 13 Sep 2019 Interim efficacy data from the phase-III CASTING trial in Multiple sclerosis (Relapsing-remitting) released by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top